|
1
|
Kiyosawa K, Umemura T, Ichijo T, et al:
Hepatocellular carcinoma: recent trends in Japan. Gastroenterology.
127:S17–S26. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Taura N, Fukushima N, Yastuhashi H, et al:
The incidence of hepatocellular carcinoma associated with hepatitis
C infection decreased in Kyushu area. Med Sci Monit. 17:PH7–PH11.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Koike K: Hepatitis C as a metabolic
disease: implication for the pathogenesis of NASH. Hepatol Res.
33:145–150. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kawaguchi T and Sata M: Importance of
hepatitis C virus-associated insulin resistance: therapeutic
strategies for insulin sensitization. World J Gastroenterol.
16:1943–52. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sumie S, Kawaguchi T, Kuromatsu R, et al:
Total and high molecular weight adiponectin and hepatocellular
carcinoma with HCV infection. PLoS One. 6:e268402011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu Q and Liu Q: Do hepatitis B virus and
hepatitis C virus co-infections increase hepatocellular carcinoma
occurrence through synergistically modulating lipogenic gene
expression? Hepatol Res. 42:733–740. 2012. View Article : Google Scholar
|
|
7
|
Torbenson M and Thomas DL: Occult
hepatitis B. Lancet Infect Dis. 2:479–486. 2002. View Article : Google Scholar
|
|
8
|
Blackard JT, Martin CM, Sengupta S and
Forrester J: Limited infection with occult hepatitis B virus in
drug users in the USA. Hepatol Res. 43:413–417. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koike K, Kobayashi M, Gondo M, Hayashi I,
Osuga T and Takada S: Hepatitis B virus DNA is frequently found in
liver biopsy samples from hepatitis C virus-infected chronic
hepatitis patients. J Med Virol. 54:249–255. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fukuda R, Ishimura N, Niigaki M, et al:
Serologically silent hepatitis B virus coinfection in patients with
hepatitis C virus-associated chronic liver disease: clinical and
virological significance. J Med Virol. 58:201–207. 1999. View Article : Google Scholar
|
|
11
|
Nirei K, Kaneko M, Moriyama M and Arakawa
Y: The clinical features of chronic hepatitis C are not affected by
the coexistence of hepatitis B virus DNA in patients negative for
hepatitis B surface antigen. Intervirology. 43:95–101. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mrani S, Chemin I, Menouar K, et al:
Occult HBV infection may represent a major risk factor of
non-response to antiviral therapy of chronic hepatitis C. J Med
Virol. 79:1075–1081. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Berberova M, Mendizova A, Popchristova E,
Krastev N and Genov J: Disease and treatment outcome in chronic
active hepatitis C with occult HBV infection.
Hepatogastroenterology. 50:2009–2012. 2003.PubMed/NCBI
|
|
14
|
Squadrito G, Pollicino T, Cacciola I, et
al: Occult hepatitis B virus infection is associated with the
development of hepatocellular carcinoma in chronic hepatitis C
patients. Cancer. 106:1326–1330. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cacciola I, Pollicino T, Squadrito G,
Cerenzia G, Orlando ME and Raimondo G: Occult hepatitis B virus
infection in patients with chronic hepatitis C liver disease. N
Engl J Med. 341:22–26. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hasegawa I, Orito E, Tanaka Y, et al:
Impact of occult hepatitis B virus infection on efficacy and
prognosis of interferon-alpha therapy for patients with chronic
hepatitis C. Liver Int. 25:247–253. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ikeda K, Marusawa H, Osaki Y, et al:
Antibody to hepatitis B core antigen and risk for hepatitis
C-related hepatocellular carcinoma: a prospective study. Ann Intern
Med. 146:649–656. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kawaguchi T, Izumi N, Charlton MR and Sata
M: Branched-chain amino acids as pharmacological nutrients in
chronic liver disease. Hepatology. 54:1063–1070. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sakata M, Kawaguchi T, Taniguchi E, Abe M,
Koga H and Sata M: Quick and simple method for increasing the
reduced albumin fraction in human serum albumin preparations by
using stronger neo-minophagen C. Hepatol Res. 41:1120–1125. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nagao Y and Sata M: Serum albumin and
mortality risk in a hyperendemic area of HCV infection in Japan.
Virol J. 7:3752010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pacella CM, Francica G, Di Lascio FM, et
al: Long-term outcome of cirrhotic patients with early
hepatocellular carcinoma treated with ultrasound-guided
percutaneous laser ablation: a retrospective analysis. J Clin
Oncol. 27:2615–2621. 2009. View Article : Google Scholar
|
|
22
|
Nishikawa H, Osaki Y, Iguchi E, et al:
Radiofrequency ablation for hepatocellular carcinoma: the
relationship between a new grading system for the ablative margin
and clinical outcomes. J Gastroenterol. 48:951–965. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Muto Y, Sato S, Watanabe A, et al: Effects
of oral branched-chain amino acid granules on event-free survival
in patients with liver cirrhosis. Clin Gastroenterol Hepatol.
3:705–713. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Muto Y, Sato S, Watanabe A, et al:
Overweight and obesity increase the risk for liver cancer in
patients with liver cirrhosis and long-term oral supplementation
with branched-chain amino acid granules inhibits liver
carcinogenesis in heavier patients with liver cirrhosis. Hepatol
Res. 35:204–214. 2006.PubMed/NCBI
|
|
25
|
Kawaguchi T, Yoshida T, Harada M, et al:
Hepatitis C virus down-regulates insulin receptor substrates 1 and
2 through up-regulation of suppressor of cytokine signaling 3. Am J
Pathol. 165:1499–1508. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Itou M, Kawaguchi T, Taniguchi E, et al:
Altered expression of glucagon-like peptide-1 and dipeptidyl
peptidase IV in patients with HCV-related glucose intolerance. J
Gastroenterol Hepatol. 23:244–251. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pascal JP and Cales P: Propranolol in the
prevention of first upper gastrointestinal tract hemorrhage in
patients with cirrhosis of the liver and esophageal varices. N Engl
J Med. 317:856–861. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
The Committee of Japan Diabetes Society on
the diagnostic criteria of diabetes mellitus. Report of the
committee on the classification and diagnostic criteria of diabetes
mellitus. J Japan Diab Soc. 53:450–467. 2010.(In Japanese).
|
|
29
|
Fujiyama A, Miyanohara A, Nozaki C,
Yoneyama T, Ohtomo N and Matsubara K: Cloning and structural
analyses of hepatitis B virus DNAs, subtype adr. Nucleic Acids Res.
11:4601–4610. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Firth D: Bias reduction of maximum
likelihood estimates. Biometrika. 80:27–38. 1993. View Article : Google Scholar
|
|
31
|
Otsuka M, Uchida Y, Kawaguchi T, et al:
Fish to meat intake ratio and cooking oils are associated with
hepatitis C virus carriers with persistently normal alanine
aminotransferase levels. Hepatol Res. 42:982–989. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Taniguchi E, Kawaguchi T, Sakata M, Itou
M, Oriishi T and Sata M: Lipid profile is associated with the
incidence of cognitive dysfunction in viral cirrhotic patients: a
data-mining analysis. Hepatol Res. 43:418–424. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Adachi S, Shibuya A, Miura Y, Takeuchi A,
Nakazawa T and Saigenji K: Impact of occult hepatitis B virus
infection and prior hepatitis B virus infection on development of
hepatocellular carcinoma in patients with liver cirrhosis due to
hepatitis C virus. Scand J Gastroenterol. 43:849–856. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kao JH, Chen PJ, Lai MY and Chen DS:
Occult hepatitis B virus infection and clinical outcomes of
patients with chronic hepatitis C. J Clin Microbiol. 40:4068–4071.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shintani Y, Yotsuyanagi H, Moriya K, et
al: The significance of hepatitis B virus DNA detected in
hepatocellular carcinoma of patients with hepatitis C. Cancer.
88:2478–2486. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lok AS, Everhart JE, Di Bisceglie AM, Kim
HY, Hussain M and Morgan TR: Occult and previous hepatitis B virus
infection are not associated with hepatocellular carcinoma in
United States patients with chronic hepatitis C. Hepatology.
54:434–442. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tamori A, Nishiguchi S, Kubo S, et al:
Possible contribution to hepatocarcinogenesis of X transcript of
hepatitis B virus in Japanese patients with hepatitis C virus.
Hepatology. 29:1429–1434. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim CM, Koike K, Saito I, Miyamura T and
Jay G: HBx gene of hepatitis B virus induces liver cancer in
transgenic mice. Nature. 351:317–320. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Koike K, Moriya K, Iino S, et al:
High-level expression of hepatitis B virus HBx gene and
hepatocarcinogenesis in transgenic mice. Hepatology. 19:810–819.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
MacKinney AA Jr: Effect of aging on the
peripheral blood lymphocyte count. J Gerontol. 33:213–216. 1978.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Margolis KL, Rodabough RJ, Thomson CA,
Lopez AM and McTiernan A: Prospective study of leukocyte count as a
predictor of incident breast, colorectal, endometrial, and lung
cancer and mortality in postmenopausal women. Arch Intern Med.
167:1837–1844. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Iida M, Ikeda F, Ninomiya T, et al: White
blood cell count and risk of gastric cancer incidence in a general
Japanese population: the Hisayama study. Am J Epidemiol.
175:504–510. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Barashi N, Weiss ID, Wald O, et al:
Inflammation induced hepatocellular carcinoma is dependent on CCR5.
Hepatology. Mar 21–2013.(Epub ahead of print). View Article : Google Scholar
|
|
44
|
Pusterla T, Nèmeth J, Stein I, et al:
Receptor for advanced glycation endproducts (RAGE) is a key
regulator of oval cell activation and inflammation-associated liver
carcinogenesis in mice. Hepatology. 8:363–373. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lee FY, Lee SD, Tsai YT, Wu JC, Lai KH and
Lo KJ: Serum C-reactive protein as a serum marker for the diagnosis
of hepatocellular carcinoma. Cancer. 63:1567–1571. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dufour JF: C-reactive protein, a
prognostic marker in HCC. Hepatology. 57:2103–2105. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Assar S, Arababadi MK, Ahmadabadi BN,
Salehi M and Kennedy D: Occult hepatitis B virus (HBV) infection: a
global challenge for medicine. Clin Lab. 58:1225–1230.
2012.PubMed/NCBI
|
|
48
|
Matsuoka S, Nirei K, Tamura A, et al:
Influence of occult hepatitis B virus coinfection on the incidence
of fibrosis and hepatocellular carcinoma in chronic hepatitis C.
Intervirology. 51:352–361. 2008. View Article : Google Scholar : PubMed/NCBI
|
